Genome instability and loss of protein homeostasis: converging paths to neurodegeneration?

Anna Ainslie1,2, Wouter Huiting1, Lara Barazzuol1,2,† and Steven Bergink1,†

1Department of Biomedical Sciences of Cells and Systems, and 2Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands

Genome instability and loss of protein homeostasis are hallmark events of age-related diseases that include neurodegeneration. Several neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis are characterized by protein aggregation, while an impaired DNA damage response (DDR) as in many genetic DNA repair disorders leads to pronounced neuropathological features. It remains unclear to what degree these cellular events interconnect with each other in the development of neurological diseases. This review highlights how the loss of protein homeostasis and genome instability influence one another. We will discuss studies that illustrate this connection. DNA damage contributes to many neurodegenerative diseases, as shown by an increased level of DNA damage in patients, possibly due to the effects of protein aggregates on chromatin, the sequestration of DNA repair proteins and novel putative DNA repair functions. Conversely, genome stability is also important for protein homeostasis. For example, gene copy number variations and the loss of key DDR components can lead to marked proteotoxic stress. An improved understanding of how protein homeostasis and genome stability are mechanistically connected is needed and promises to lead to the development of novel therapeutic interventions.

1. Introduction

Age-related diseases, such as neurodegeneration and cancer, are on the rise due to an increasingly ageing population. It is estimated that the proportion of people over 60 years of age will double by 2050 [1]. Despite both being associated with age, the underlying mechanisms driving pathogenesis in neurodegenerative diseases and cancer are thought to differ greatly.

For instance, the loss of protein homeostasis is key to the pathogenesis of many neurodegenerative diseases [2,3], illustrated by the presence of protein aggregates in the affected brain areas of patients [4]. Protein homeostasis is maintained via protein quality control (PQC), which coordinates three major facets of protein fate: synthesis, folding and conformational maintenance, and degradation, as described in box 1 and reviewed elsewhere [5–7]. These phases are often overlapping; for example, folding or degradation may happen co-translationally [8].

Of the multiple hallmarks of cancer, the loss of genome stability—defined as an increase in DNA damage and mutations, as well as structural aberrations—is widely regarded as the most common underlying factor in cancer development [9–11]. Under physiological conditions, genome stability is ensured by the DNA damage response (DDR), which encompasses several DNA repair pathways, cell cycle checkpoint activation and cell death [12–14]. Endogenous and exogenous
Box 1. Protein quality control in human cells.

To maintain protein homeostasis in the complex and extremely crowded intracellular milieu, cells rely on the concerted action of molecular chaperones, synthesis regulators and protein degradation pathways. This system, commonly referred to as the protein quality control (PQC) network, guards proteome balance by surveying and controlling three major facets of protein fate.

**Protein synthesis**
Protein quality control starts at the ribosome, where the faithful translation of genetic information is maintained by ribosome-associated protein quality control (RQC). When a translating ribosome stalls on a faulty messenger RNA, this triggers the dissociation of ribosomal subunits, allowing the removal and subsequent degradation of both the mRNA molecule and the nascent polypeptide chain. Globally, translation is regulated by various signalling pathways. Under cellular stress conditions, these repress global protein synthesis, thus lowering the total protein folding burden. In parallel, they induce the selective translational of stress-responsive proteins required for cell survival.

**Protein folding and conformational maintenance**
Most polypeptides exiting the ribosome must fold into distinct, three-dimensional conformations to become functionally active proteins. To ensure that the final native state is reached, polypeptide folding generally occurs co-translationally, closely monitored through the concerted action of chain-modifying enzymes, translocation factors, molecular chaperones and other quality control components. This enables the emerging polypeptide to navigate a landscape of metastable folding intermediates, while being shielded from non-productive interactions. The majority of folded proteins are thermodynamically only marginally stable, and thus at a constant risk of becoming destabilized and misfolded, both through internal (mutations, stoichiometric imbalances) and external factors (elevated temperature, oxidative stress, heavy metals). Some proteins even require constant chaperone-surveillance to maintain functionality. When the folding capacity of the PQC network is overwhelmed, misfolded proteins can accumulate and partition into insoluble protein aggregates. However, many destabilized proteins can be refolded, or even disaggregated through chaperone intervention. In the presence of excess misfolded proteins, the transcription of additional PQC network factors is induced to restore protein homeostasis.

**Protein degradation**
When proteins are in excess, no longer needed, or when they misfold but cannot be refolded, they are removed from the proteome and recycled. Most protein degradation takes place via two intracellular proteolytic systems: the ubiquitin-proteasome system (UPS) and the autophagy-lysosomal system. The bulk of protein degradation is executed by the UPS. This is a highly specific pathway that requires target proteins to be tagged with ubiquitin (ubiquitylation) and directing them to the proteasome, where they are unfolded and subsequently degraded. Protein molecules that cannot be turned over by the proteasome, like large protein aggregates, or even entire organelles, are degraded via the autophagy-lysosomal pathway. In this pathway, a double-membrane vesicle engulfs sequestered cargo proteins and then fuses with a lysosome, wherein the inner membrane and cargo are digested. Whereas this system generally acts to degrade bulk cargo, (chaperone-mediated) selective sub-pathways that directly target substrates to lysosome exist as well. Although the UPS and the autophagy-lysosomal system are two distinct pathways, extensive crosstalk allows them to compensate for each other when needed.
sources cause different types of DNA damage that are repaired by distinct pathways.

**Non-homologous end joining and homologous recombination**
DNA double-strand breaks (DSBs) occur as a result of the breakage of both strands of the DNA. DSBs are repaired by two main pathways, non-homologous end joining (NHEJ) and homologous recombination (HR), whose engagement depends on cell cycle phases and chromatin accessibility. While HR and NHEJ are both available during brain development, in the largely post-mitotic cells of the mature brain DSB repair is largely restricted to NHEJ.

**Base excision repair and single-strand break repair**
Base modifications and single-strand breaks (SSBs), which can occur by direct damage of one DNA strand or as a result of the removal of a damaged base by DNA glycosylases, are common in the mature brain due to oxidative stress. Base modifications and SSBs are repaired by two partially overlapping pathways, base excision repair (BER) and SSB repair pathways, respectively.

**Mismatch repair**
Base mismatches, small insertions and deletions, arising during DNA replication, are repaired by the mismatch repair (MMR) pathway. This type of damage is less common in the largely post-mitotic mature brain.

**Nucleotide excision repair and transcription-coupled nucleotide excision repair**
Structurally unrelated DNA lesions in non-transcribed DNA, such as helix-distorting lesions, bulky chemical adducts and intrastrand cross-links, are repaired by the nucleotide excision repair (NER) pathway. Along with this NER pathway (also called global genome NER pathway (GG-NER)), transcription-coupled NER (TC-NER) can occur in response to long-term stalling of replication. These two pathways are relatively similar and only differ in the way the lesion is detected. In the brain, these lesions are often a consequence of oxidative stress and transcriptional interference.

**DNA–protein cross-link repair pathways**
DNA–protein cross-links (DPCs) constitute a separate class of DNA lesions characterized by protein adducts to DNA caused by endogenous metabolites, other DNA repair intermediates and many chemotherapeutic agents. Repair of these lesions involves three main components based on: the DNA targeted by nucleases; the protein adduct degraded by DNA-dependent proteases and the covalent cross-link between the DNA and the protein adduct that can be hydrolysed by tyrosyl-DNA phosphodiesterases (TDPs). Defects in DPC repair have a detrimental impact on the brain.

The developing and mature brain is susceptible to various forms of endogenous and exogenous DNA damage, which are repaired by distinct pathways.

**Box 2. DNA repair pathways of relevance for the brain.**

| type of DNA damage: | DSB | SSB, abasic site, uracil | A–G, T–C mismatch, small insertion/deletion | helix-distorting lesion, bulky adduct, intrastrand cross-link | DNA–protein cross-link |
|---------------------|-----|-------------------------|------------------------------------------|------------------------------------------------|-----------------------|
| DNA repair pathway: | HR, NHEJ | SSB, BER | MMR | GG-NER, TC-NER | DPC repair pathways |

**Non-homologous end joining and homologous recombination**
DNA double-strand breaks (DSBs) occur as a result of the breakage of both strands of the DNA. DSBs are repaired by two main pathways, non-homologous end joining (NHEJ) and homologous recombination (HR), whose engagement depends on cell cycle phases and chromatin accessibility. While HR and NHEJ are both available during brain development, in the largely post-mitotic cells of the mature brain DSB repair is largely restricted to NHEJ.

**Base excision repair and single-strand break repair**
Base modifications and single-strand breaks (SSBs), which can occur by direct damage of one DNA strand or as a result of the removal of a damaged base by DNA glycosylases, are common in the mature brain due to oxidative stress. Base modifications and SSBs are repaired by two partially overlapping pathways, base excision repair (BER) and SSB repair pathways, respectively.

**Mismatch repair**
Base mismatches, small insertions and deletions, arising during DNA replication, are repaired by the mismatch repair (MMR) pathway. This type of damage is less common in the largely post-mitotic mature brain.

**Nucleotide excision repair and transcription-coupled nucleotide excision repair**
Structurally unrelated DNA lesions in non-transcribed DNA, such as helix-distorting lesions, bulky chemical adducts and intrastrand cross-links, are repaired by the nucleotide excision repair (NER) pathway. Along with this NER pathway (also called global genome NER pathway (GG-NER)), transcription-coupled NER (TC-NER) can occur in response to long-term stalling of replication. These two pathways are relatively similar and only differ in the way the lesion is detected. In the brain, these lesions are often a consequence of oxidative stress and transcriptional interference.

**DNA–protein cross-link repair pathways**
DNA–protein cross-links (DPCs) constitute a separate class of DNA lesions characterized by protein adducts to DNA caused by endogenous metabolites, other DNA repair intermediates and many chemotherapeutic agents. Repair of these lesions involves three main components based on: the DNA targeted by nucleases; the protein adduct degraded by DNA-dependent proteases and the covalent cross-link between the DNA and the protein adduct that can be hydrolysed by tyrosyl-DNA phosphodiesterases (TDPs). Defects in DPC repair have a detrimental impact on the brain.

**Box 2**. DNA repair pathways of relevance for the brain.

The developing and mature brain is susceptible to various forms of endogenous and exogenous DNA damage, which are repaired by distinct pathways.

**Non-homologous end joining and homologous recombination**
DNA double-strand breaks (DSBs) occur as a result of the breakage of both strands of the DNA. DSBs are repaired by two main pathways, non-homologous end joining (NHEJ) and homologous recombination (HR), whose engagement depends on cell cycle phases and chromatin accessibility. While HR and NHEJ are both available during brain development, in the largely post-mitotic cells of the mature brain DSB repair is largely restricted to NHEJ.

**Base excision repair and single-strand break repair**
Base modifications and single-strand breaks (SSBs), which can occur by direct damage of one DNA strand or as a result of the removal of a damaged base by DNA glycosylases, are common in the mature brain due to oxidative stress. Base modifications and SSBs are repaired by two partially overlapping pathways, base excision repair (BER) and SSB repair pathways, respectively.

**Mismatch repair**
Base mismatches, small insertions and deletions, arising during DNA replication, are repaired by the mismatch repair (MMR) pathway. This type of damage is less common in the largely post-mitotic mature brain.

**Nucleotide excision repair and transcription-coupled nucleotide excision repair**
Structurally unrelated DNA lesions in non-transcribed DNA, such as helix-distorting lesions, bulky chemical adducts and intrastrand cross-links, are repaired by the nucleotide excision repair (NER) pathway. Along with this NER pathway (also called global genome NER pathway (GG-NER)), transcription-coupled NER (TC-NER) can occur in response to long-term stalling of replication. These two pathways are relatively similar and only differ in the way the lesion is detected. In the brain, these lesions are often a consequence of oxidative stress and transcriptional interference.

**DNA–protein cross-link repair pathways**
DNA–protein cross-links (DPCs) constitute a separate class of DNA lesions characterized by protein adducts to DNA caused by endogenous metabolites, other DNA repair intermediates and many chemotherapeutic agents. Repair of these lesions involves three main components based on: the DNA targeted by nucleases; the protein adduct degraded by DNA-dependent proteases and the covalent cross-link between the DNA and the protein adduct that can be hydrolysed by tyrosyl-DNA phosphodiesterases (TDPs). Defects in DPC repair have a detrimental impact on the brain.

**Box 2. DNA repair pathways of relevance for the brain.**

| type of DNA damage: | DSB | SSB, abasic site, uracil | A–G, T–C mismatch, small insertion/deletion | helix-distorting lesion, bulky adduct, intrastrand cross-link | DNA–protein cross-link |
|---------------------|-----|-------------------------|------------------------------------------|------------------------------------------------|-----------------------|
| DNA repair pathway: | HR, NHEJ | SSB, BER | MMR | GG-NER, TC-NER | DPC repair pathways |
Table 1. Neurodegenerative disease models and DNA damage.

| Evidence of increased DNA damage | Evidence of increased DDR | Evidence of DNA binding |
|---------------------------------|---------------------------|------------------------|
| **Neutral comet assay**          |                           |                        |
| AD amyloid-β OE                 | mouse dentate gyrus [31]   |                        |
| AD amyloid-β fibrils            | rat adrenal medulla cells [32] |                        |
| Tau KO                          | mouse cortex [34]          | mouse hippocampus [34] |
| Tau aggregation                 |                           |                        |
| AD patients                     |                           |                        |
| PD α-synuclein OE               | SH-SYSY α-syn [39]         | mouse nigral dopaminergic neurons [40] |
| PD α-synuclein fibrils          | mDNA in mouse brainstem, neocortex, motor neurons [30] | DNA damage prevented by antioxidant [40] |
| PD patients                     |                           | mouse nigral dopaminergic neurons [40] |
| PD patients, elevated levels of OGG1 [42–44] |                           |                        |
| **Alkaline comet assay**         |                           |                        |
| AD amyloid-β OE                 | mouse dentate gyrus [31]   |                        |
| AD amyloid-β fibrils            | rat adrenal medulla cells [32] |                        |
| Tau KO                          | mouse cortex [34]          | mouse hippocampus [34] |
| Tau aggregation                 |                           |                        |
| AD patients                     |                           |                        |
| PD α-synuclein OE               | SH-SYSY α-syn [39]         | mouse nigral dopaminergic neurons [40] |
| PD α-synuclein fibrils          | mDNA in mouse brainstem, neocortex, motor neurons [30] | DNA damage prevented by antioxidant [40] |
| PD patients, elevated levels of OGG1 [42–44] |                           |                        |
| **TUNEL assay**                 |                           |                        |
| AD amyloid-β OE                 | mouse dentate gyrus [31]   |                        |
| AD amyloid-β fibrils            | rat adrenal medulla cells [32] |                        |
| Tau KO                          | mouse cortex [34]          | mouse hippocampus [34] |
| Tau aggregation                 |                           |                        |
| AD patients                     |                           |                        |
| PD α-synuclein OE               | SH-SYSY α-syn [39]         | mouse nigral dopaminergic neurons [40] |
| PD α-synuclein fibrils          | mDNA in mouse brainstem, neocortex, motor neurons [30] | DNA damage prevented by antioxidant [40] |
| PD patients, elevated levels of OGG1 [42–44] |                           |                        |
| **DNA electrophoresis**         |                           |                        |
| AD amyloid-β OE                 | mouse dentate gyrus [31]   |                        |
| AD amyloid-β fibrils            | rat adrenal medulla cells [32] |                        |
| Tau KO                          | mouse cortex [34]          | mouse hippocampus [34] |
| Tau aggregation                 |                           |                        |
| AD patients                     |                           |                        |
| PD α-synuclein OE               | SH-SYSY α-syn [39]         | mouse nigral dopaminergic neurons [40] |
| PD α-synuclein fibrils          | mDNA in mouse brainstem, neocortex, motor neurons [30] | DNA damage prevented by antioxidant [40] |
| PD patients, elevated levels of OGG1 [42–44] |                           |                        |
| **Oxidative DNA damage**        |                           |                        |
| AD amyloid-β OE                 | mouse dentate gyrus [31]   |                        |
| AD amyloid-β fibrils            | rat adrenal medulla cells [32] |                        |
| Tau KO                          | mouse cortex [34]          | mouse hippocampus [34] |
| Tau aggregation                 |                           |                        |
| AD patients                     |                           |                        |
| PD α-synuclein OE               | SH-SYSY α-syn [39]         | mouse nigral dopaminergic neurons [40] |
| PD α-synuclein fibrils          | mDNA in mouse brainstem, neocortex, motor neurons [30] | DNA damage prevented by antioxidant [40] |
| PD patients, elevated levels of OGG1 [42–44] |                           |                        |
| γ-H2AX                          |                           |                        |
| AD amyloid-β OE                 | mouse cortex, hippocampus [31] | mouse primary neuronal α-syn [31] |
| AD amyloid-β fibrils            | fibrilar amyloid-β treatment of naked scDNA [33] | mouse primary neuronal α-syn [31] |
| Tau KO                          | mouse cortex and hippocampus, TauKO rescues amyloid-β-induced DNA damage [31] |
| Tau aggregation                 |                           |                        |
| AD patients                     |                           |                        |
| PD α-synuclein OE               | SH-SYSY α-syn [39]         | mouse nigral dopaminergic neurons [40] |
| PD α-synuclein fibrils          | mDNA in mouse brainstem, neocortex, motor neurons [30] | DNA damage prevented by antioxidant [40] |
| PD patients, elevated levels of OGG1 [42–44] |                           |                        |
| 53BP1 and ATM                   | mouse nigral dopaminergic neurons [40] |
| AD patient cortex [37,38]       |                           |                        |
| AD patient cortex [37]          |                           |                        |
| HAP1 cells after bleomycin treatment [41] | mouse nigral dopaminergic neurons [40] |
| HAP1 cells after bleomycin treatment [41] | mouse nigral dopaminergic neurons [40] |
| α-synuclein and dsDNA, EMSA [41] |                           |                        |
| PD patients, elevated levels of OGG1 [42–44] |                           |                        |
| Human HAP1 α-syn [41]           | mouse cortical neurons [41] |
| Mouse cortical neurons [41]    |                           |                        |
| (Continued.)                    |                           |                        |
| evidence of increased DNA damage | evidence of increased DDR | evidence of DNA binding |
|----------------------------------|---------------------------|------------------------|
| **neutral comet assay** | **alkaline comet assay** | **TUNEL assay** | **DNA electrophoresis** | **oxidative DNA damage** | **γ-H2AX** | **S3RIP1 and ATM** |
| ALS | TDP-43 KO | SH-SY5Y cells | [45] | SH-SY5Y cells | [46] | SH-SY5Y cells | [46] | evidence of increased DNA binding |
| SOD1 NLS or mutant | SH-SY5Y cells, NLS-SOD1 | neutral comet assay | SOD1 rescues DNA damage | [46] | SOD1G93A inhibits translocation of HDAC1 to the nucleus | [47] |
| FUS HD | SH-SY5Y cells | alkaline comet assay | SOD1G93A inhibits translocation of HDAC1 to the nucleus | [47] |
| mutant FUS | mouse primary cortical neurons | TUNEL assay | mouse cortex and spinal cord | [50] |
| ALS patients | ALS patient PBMCs | ALS patient spinal cord tissues | ALS patient spinal cord tissues with aggregated TDP-43 | ALS patient spinal cord tissues with aggregated TDP-43 |
| ALS patients with aggregated SOD1 | ALS patient spinal cord tissues with aggregated TDP-43 | ALS patient spinal cord tissues with aggregated TDP-43 |
| HD | mutant htt | rat primary cortical neurons | HD patients | HD patient neurons | [51] |
| HD patients | | | | | [51] |
begun to shed light on potential mechanisms linking DNA damage and neurodegeneration [56]. This review presents recent evidence of protein aggregates directly causing DNA damage: either double-strand breaks (DSBs) or oxidative DNA damage. Additionally, typical examples that illustrate the mechanisms by which aggregate-forming proteins interfere with DNA repair pathways in different models of neurodegenerative diseases are discussed (figure 1). Lastly, an overview is given of how DNA damage itself, by leading to mistranslation and misfolding of proteins, can perturb protein homeostasis and lead to neurodegeneration.

2. DNA damage due to protein aggregation in neurodegenerative diseases

The accumulation of DNA damage has been reported in several neurodegenerative diseases including AD, PD, HD and ALS. Different types of DNA damage have been identified in models of neurodegenerative diseases and post-mortem human brain tissues, mostly DNA DSBs and oxidative DNA damage (figure 1 and table 1). Here, we summarize the evidence that protein aggregates can cause DNA damage either directly or via oxidative stress.

DNA damage can be detected in several different ways, using physical methods that reveal the DNA damage directly such as electrophoresis assays (e.g. pulsed-field gel electrophoresis and neutral comet assays), which are used to detect DSBs, and alkaline comet assays, which can detect both single-strand breaks (SSBs) and DSBs [57]. DNA damage can also be inferred from the detection of activated DDR components, such as the phosphorylation of the histone 2AX (γ-H2AX), which occurs early at sites of DNA damage [58]. The recruitment of other DDR components, such as 53BP1 and ATM, can also be used to indirectly detect DNA damage [59–61]. These last methods do not detect the damage directly, but rather measure a response to DNA damage and can be used as an estimate of the actual amount of DNA damage. Moreover, they do not always accurately report on the type of DNA damage that is present. For example, the phosphorylation of H2AX is well suited as a general marker of genotoxicity but it marks various types of lesions and not only DSBs [62].

2.1. Protein aggregates can directly cause DNA double-strand breaks

Several studies have linked AD with a higher frequency of DNA damage markers such as γ-H2AX in affected brain areas [37,38]. Moreover, neural activity-induced DNA damage was exacerbated in an AD mouse model with elevated amyloid-β levels [31]. This finding was supported by experiments using mouse primary neuronal cells, suggesting that amyloid-β oligomers are sufficient to increase the level of DSBs, detected using a neutral comet assay and by staining for DDR components γ-H2AX and 53BP1 [31].

It has been proposed that protein aggregates can directly cause DNA breaks. In an early in vitro study, incubating naked supercoiled DNA with AD-associated fibrillar amyloid-β-protein alone resulted in the formation of circular and linear forms of DNA, suggesting that amyloid-β fibrils are sufficient to induce DNA breaks [33]. Furthermore, treatment with a protein–DNA interaction inhibitor prevented DNA fragmentation, suggesting
Figure 2. Neurodegenerative disease-associated proteins and their interactions with the DDR under physiological conditions (blue) and neurodegenerative pathological conditions (red). APP, amyloid precursor protein.

By contrast, other studies have reported that nuclear Tau protects the DNA from damage in cell culture under stress conditions [67] (figure 2). A recent in vivo study showed that Tau deficient mice without elevated amyloid-β have higher levels of DNA damage, detected with an alkaline comet assay in various parts of the brain including the cortex and hippocampus [34]. Additionally, AD-associated aggregation of Tau loses its ability to bind to DNA [35,36]; thus, it has been postulated that the loss of Tau from the nucleus could contribute to the accumulation of DNA damage as observed in AD patient brains. Alternatively, based on these results, it cannot be excluded that Tau has an active role in facilitating DNA repair.

2.2. Protein aggregation triggers oxidative stress and oxidative DNA damage

A major hallmark of neurodegeneration is oxidative stress [68]. Oxidative stress leads to mitochondrial dysfunction, which is present in various neurodegenerative diseases, and there are multiple mechanisms linking mitochondrial dysfunction and protein homeostasis [69]. Additionally, mitochondrial dysfunction itself results in increased levels of reactive oxygen species (ROS), creating a positive feedback loop of oxidative stress. The relationship between mitochondrial dysfunction, neurodegenerative diseases and ageing has been extensively reviewed [70–73].

As neurons already inherently generate high levels of ROS due to their active metabolic state [74], this has fuelled the hypothesis that ROS-mediated toxicity plays a central role in the pathophysiology of many neurodegenerative diseases. However, it is not entirely clear how oxidative stress relates to

that DNA break formation is dependent on amyloid-β binding to DNA [33]. However, it is unclear whether amyloid-β has nucleolytic activity, or whether incubation of naked DNA with any aggregated protein would lead to DNA breaks. High levels of aggregation-prone luciferase also impair the DDR [63], implying that the effects of aggregated amyloid-β are indeed non-specific. Of note, amyloid-β plaques are usually extracellular [64] and therefore not in close proximity to nuclear DNA, making it less likely that this contributes to the clinical manifestations of AD.

A similar direct effect on the integrity of DNA has been proposed for α-synuclein, aggregation of which (in the form of Lewy bodies) is a pathological hallmark of PD and several other neurodegenerative disorders [65]. Recombinant α-synuclein has been found to cause DNA breaks in vitro, and its misfolding and oligomerization exacerbates damage even further [39]. Using a human neuroblastoma cell line, Vasquez et al. [39] went on to show that α-synuclein interacts with chromatin, and that the nuclear localization of α-synuclein results in an increase in DNA damage, as detected by an alkaline comet assay. The relevance for the disease is still unclear as increased DSB levels have, to our knowledge, not yet been reported in PD patients or in any of the other synucleinopathies.

Next to the presence of extracellular amyloid-β aggregates, AD is also associated with the formation of Tau aggregates [66]. Next to amyloid-β and α-synuclein, Tau has been suggested to influence genome integrity as well. Interestingly, the deletion of Tau in an AD mouse model characterized by elevated amyloid-β levels reduced γ-H2AX levels in neurons to wild-type control levels [31]. Such a response also occurred with Tau heterozygosity. This suggests that the detrimental effect of amyloid-β on DNA stability depends on the presence of Tau [31] and argues against direct DNA damage by fibrillar amyloid-β protein.
DNA damage and to a loss of protein homeostasis in this context. Here, we will focus on studies where changes in oxidative stress were observed in disease models in response to an accumulation of neurodegeneration-associated proteins.

The induction of protein aggregates triggers oxidative stress in several models, subsequently leading to oxidative DNA damage in neurons [24]. For example, mammalian neuronal AD cells treated with a toxic amyloid-β peptide fragment (amyloid-β_{25–33}) showed increased ROS levels [32]. Additionally, in PD patients, oxidative DNA damage has been detected in the substantia nigra, as shown by elevated levels of 8-oxoguanine (8-oxoG) and the activation of DNA repair enzymes [42–44].

Other studies have found that α-synuclein also mediates an increase in DNA damage via oxidative stress. Injection of either cDNA encoding α-synuclein (using an AAV delivery system) or human α-synuclein pre-formed fibrils (PFF-syn) in the mouse substantia nigra and striatum increased DNA damage and activated the DDR [40]. Both AAV-syn- and PFF-syn-treated mice displayed α-synuclein aggregates, visible six and four months after injection, respectively, alongside increased levels of DNA damage, detected by staining for foci of DDR components γ-H2AX and 53BP1. In these in vivo models, protein aggregation often occurs relatively late, suggesting that it is not the protein aggregates themselves, but rather early, indirect mechanisms that underlie the increase in DNA damage. Indeed, PFF-syn-induced DNA damage and the activation of the DDR in the dopaminergic cell line SH-SY5Y were prevented by administration of the antioxidant N-acetylcysteine (NAC) [40], indicating that the elevated DNA damage observed in these PD models is occurring indirectly via oxidative stress induced by α-synuclein aggregates.

Oxidative stress is also thought to play a role in ALS [75], mostly via superoxide dismutase (SOD1), an enzyme that catalyzes the breakdown of toxic superoxide radicals, which is associated with ALS [76]. A study of ALS patient blood cells expressing wild-type SOD1 but with high levels of cytoplasmic SOD1 aggregates revealed increased DNA damage, detected with an alkaline comet assay [46]. The opposite was true in ALS patient blood cells with nuclear SOD1 [46]. Furthermore, in human neuroblastoma cell lines, NLS-SOD1 rescued H2O2-ALS patient blood cells with nuclear SOD1 [46]. Furthermore, initial correlative studies of AD patient brain tissues, detected using a cell-free DNA end-joining assay [29]. Next to NHEJ, reduced neuronal HR has also been suggested in AD. The overexpression of amyloid-β in mice results in a reduction of BRCA1 in neurons, and the depletion of neuronal BRCA1 results in increased levels of DNA damage marker γ-H2AX in the hippocampus [83] (figure 2). The heterodimer BRCA1/BARD1 has E3 ligase activity and redirects DSβ repair through HR, suggesting that a decreased level of BRCA1 reduces neuronal HR activity [84]. Furthermore, initial correlative studies of AD patient brain tissues showed a reduction in Mre11 compared with age-matched non-dementia controls [28]. Mre11, together with Rad50 and Nbs1, forms the MRN complex that recognizes DSBs, initiates DSB resection and triggers cell cycle checkpoint activation. Consequently, a reduction of Mre11 would cause both NHEJ and HR defects [85]. However, currently, it is unclear whether this decrease in BRCA1 or Mre11 protein levels are directly leading to reduced NHEJ or HR efficiency in the brain of AD patients. The reduced expression of these two core DSβ repair proteins illustrates how protein aggregation by impeding protein expression may influence DNA repair capacity.

3. Protein aggregation impairs DNA repair pathways

Many studies have suggested that the aggregation of neurodegeneration-associated proteins can interfere with the DDR via several mechanisms (figure 1) [82]. Multiple distinct DNA repair pathways deal with different types of DNA damage (box 2), including non-homologous end joining (NHEJ), homologous recombination (HR) and base excision repair (BER) [13]. Here, we selected some examples that illustrate how defects in DNA repair pathways are associated with different aggregating protein species, and how they are affected in neurodegenerative disorders.

3.1. Alzheimer’s disease: amyloid-β

Evidence of potential mechanisms linking protein aggregation and DSβ repair capacity includes a decrease in NHEJ activity in post-mortem AD patient brain tissues, detected using a cell-free DNA end-joining assay [29]. Next to NHEJ, reduced neuronal HR has also been suggested in AD. The overexpression of amyloid-β in mice results in a reduction of BRCA1 in neurons, and the depletion of neuronal BRCA1 results in increased levels of DNA damage marker γ-H2AX in the hippocampus [83] (figure 2). The heterodimer BRCA1/BARD1 has E3 ligase activity and redirects DSβ repair through HR, suggesting that a decreased level of BRCA1 reduces neuronal HR activity [84]. Furthermore, initial correlative studies of AD patient brain tissues showed a reduction in Mre11 compared with age-matched non-dementia controls [28]. Mre11, together with Rad50 and Nbs1, forms the MRN complex that recognizes DSBs, initiates DSB resection and triggers cell cycle checkpoint activation. Consequently, a reduction of Mre11 would cause both NHEJ and HR defects [85]. However, currently, it is unclear whether this decrease in BRCA1 or Mre11 protein levels are directly leading to reduced NHEJ or HR efficiency in the brain of AD patients. The reduced expression of these two core DSβ repair proteins illustrates how protein aggregation by impeding protein expression may influence DNA repair capacity.

Similar to the reduced expression of DSβ repair proteins, the reduced expression of BER components uracil-DNA glycosylase (UDG1) and 8-oxoguanine DNA glycosylase (OGG1) was also observed in AD patient brains, suggesting a decreased capacity to repair oxidative DNA damage [86] (figure 2). Furthermore, a correlation between reduced levels of BER components and incision activity, and an abundance of neurofibrillary tangles were found in patients with amnestic mild cognitive impairment (aMCI), a condition that is often observed in early AD progression [86]. However, no correlation was found between reduced BER and the number of amyloid-β plaques in this patient dataset [86]. Together these results suggest that deficiencies in BER activity occur early in AD progression, preventing the repair of oxidative damage and indirectly causing DNA damage. In line with this, reducing direct DNA damage. However, whether these proteins indeed cause DNA damage directly in vivo is less clear and most evidence points to an indirect role, for example, via the induction of oxidative damage. Alternatively, protein aggregation can also influence genome stability via inhibition of DDR pathways.
BER capacity in amyloid-β overexpressing mice exacerbates the AD-like phenotypes [87].

3.2. Parkinson’s disease: α-synuclein

The physiological activity of α-synuclein has been proposed to play a more direct role in DNA repair. Knockout of α-synuclein in human cell culture inhibits DNA repair, and α-synuclein colocalizes with DSB repair components in response to bleomycin-induced DNA damage in human cell culture [41]. In the same study, an *in vitro* biochemical assay suggested that α-synuclein facilitates TR ligase-mediated DNA end joining [41] (figure 2). A physiological role for α-synuclein in the nucleus has previously been inferred by a study in which neuronal cytoplasmic α-synuclein inclusions led to reduced levels of soluble α-synuclein in the nucleus [41,88]. Therefore, it is possible that these cytoplasmic inclusions result in pathologically low levels of α-synuclein in the nucleus, thereby reducing DSB repair capacity via its proposed role in NHEJ [41] (figure 2).

3.3. Amyotrophic lateral sclerosis: FUS, TDP-43 and SOD1

Changes to DSB repair mechanisms have also been observed in ALS models. For example, fused in sarcoma (FUS) is an RNA-binding protein that forms aggregates in ALS patients [89,90]. ALS patients with FUS mutations as well as FUS mutant mouse models display high levels of genome instability [49,50,91]. Whereas recombiant and endogenous FUS colocalizes to sites of radiation-induced DNA damage [92,93], the ALS-associated FUS mutant is unable to accumulate at sites of DNA damage [93]. Furthermore, ALS-associated FUS mutants have an impaired interaction with the chromatin remodeler histone deacetylase 1 (HDAC1), which plays a role in facilitating DNA repair [49,94,95]. This impaired interaction inhibits HDAC1 activity and therefore perturbs DSB repair [49]. The depletion of FUS resulted in reduced activity of both HR and NHEJ, suggesting that the involvement of FUS in DDR takes place upstream of these pathways [92]. However, it has also been postulated that FUS may also play a role in BER and SSB repair [93]. In the case of SSB repair, instead of an early function as in DSB repair, FUS facilitates the ligation of DNA nicks in motor neurons via recruitment of XRCC1 and LigIII to sites of DNA damage [48]. Additionally, aggregated ALS-associated mutant SOD1 has been shown to impair DNA repair in mouse motor neurons by inhibiting the translocation of the HDAC1/FUS complex to the nucleus [47].

TDP-43 is another RNA/DNA-binding protein that forms aggregates in ALS patients and models [96,97]. While TDP-43 is nuclear-localized under physiological conditions, it forms cytoplasmic aggregates in neurons of ALS patients [98]. The loss of TDP-43 from the nucleus in neuroblastoma SH-SY5Y cells results in increased levels of DSBs and DDR activity [45]. Furthermore, the loss of nuclear TDP-43 in ALS patients correlates strongly with TDP-43 aggregation and increased DNA damage [45]. This loss of genome stability is thought to be due to the reduction of NHEJ activity, as TDP-43 acts as a scaffold for recruitment of the XRCC4–LigIV NHEJ ligation complex in neural progenitor stem cells (NPCs) [45] (figure 2).

The aggregation of FUS, TDP-43 and SOD1 leads to reduced availability or impaired localization that limits their cellular function in genome maintenance, similarly to the proposed mechanism for the impact of α-synuclein aggregation on DSB repair [45,47,48]. In addition to the aggregation of these three infamous proteins, there are more links between ALS-associated genes and protein homeostasis. For example, senataxin (SETX), a helicase involved in the resolution of R-loops, is connected to autophagy [99]. SETX has also been linked to the ubiquitin-proteasome system (UPS), which plays a central role in PQC (box 1) [100,101]. Interestingly, SETX is also linked to the DDR [102]. In fact, several other ALS-associated genes such as NIMA-related kinase 1 (NEK1), p97 (also called VCP) and Ubiquilin 2 (UBQLN2) also have direct links to the DDR and proteostasis [103–110]. However, currently, it is unclear whether the mutant, ALS-associated, forms of these genes impede the DDR and if this influences the protein homeostasis.

3.4. Huntington’s disease: Huntingtin

An alternative mechanism by which cytoplasmic aggregates can inhibit DDR is via the sequestration of DNA repair proteins. This has been observed in HD models; for example, HD-associated Huntingtin (Htt) mutant impairs DSB repair by sequestering the NHEJ-component Ku70 [51]. Mutant Htt was shown to colocalize and interact with Ku70, resulting in reduced Ku70 DNA-binding [51] (figure 2). Hence, the observed increased DNA damage in HD cellular and mouse models could be due to the impairment of DSB repair via NHEJ [51]. In a later study, the expression of polyQ inclusion bodies in human cells resulted in a failure to recruit 53BP1 to DSBs, where 53BP1 is known to redirect DSB repair through NHEJ, in line with a reduced NHEJ efficiency [63]. Moreover, mutant Htt sequesters the DDR kinase ATM in the cytoplasm, thereby contributing to reduced DSB repair in the nucleus [111]. Additionally, Htt co-localizes and interacts with BER proteins in response to oxidative stress [112].

HD-patient peripheral blood mononuclear cells also showed nuclear DNA damage due to a reduced activity of the BER pathway, demonstrated by reduced expression of BER components, including OGG1 [113]. Similarly, in transgenic HD cell and mouse models, mutant Htt impairs the function of the DNA repair enzyme polynucleotide kinase 3’-phosphatase (PNKP), disrupting BER-mediated DNA repair [114] (figure 2). These studies suggest that mutant Htt indirectly causes DNA damage by impairing BER activity. However, as mentioned above, the expression of aggregation-prone luciferase also impaired activation of the DDR [63]. Therefore, the loss of DDR in response to protein aggregation may not be specific to any particular protein, as it can also be caused by artificially created aggregates [63].

3.5. Spinocerebellar ataxia type 3: Ataxin-3

The sequestration of DNA repair proteins into Htt aggregates is similar to a mechanism observed in models of another polyQ protein, Ataxin-3, related to Machado-Joseph disease, also known as spinocerebellar ataxia type 3 (SCA3). Ataxin-3 is a deubiquitinating enzyme and expansions of the polyQ tract result in the formation of Ataxin-3 aggregates [115].

It has been claimed that the pathogenicity of mutant Ataxin-3 is due to the sequestration of DDR proteins in cytoplasmic inclusions [116,117]. For example, similar to mutant Htt, mutant aggregated Ataxin-3 inactivates the BER component PNKP in SCA3 cellular and mouse models, as well as in...
human brain samples [118]. Considering the persistent DNA damage also observed in these models, it is suggested that the formation of aggregates in SCA3 inhibits PNKP-mediated DNA repair mechanisms, causing genome instability [118]. Other studies pointed to the role of Ataxin-3 in DNA repair, independent of the expanded polyQ tract. The loss of Ataxin-3 in human cell cultures impaired the recruitment of DSB repair proteins 53BP1 and RNF168 to sites of DNA damage, and consequently lowered the levels of NHEJ and HR [119,120] (figure 2). These results show that the deubiquitinase activity of Ataxin-3 as part of the p97 hub is important for the DDR [119,120].

3.6. DNA repair proteins and aggregation

Strikingly, many DNA repair factors either directly aggregate or are sequestered into protein aggregates [118,121]. This indicates that the processes of protein aggregation and genome maintenance are somehow intrinsically connected. A possible explanation lies in the fact that, similar to most RNA-binding proteins, many DNA-binding proteins, including those involved in the DDR, rely heavily on regions of intrinsic disorder (IDRs) to perform their function [122,123]. These regions are thought to allow proteins to be structurally flexible and yet enable them to engage many different binding partners (i.e. proteins and nucleic acids) with high specificity [124].

Recently, a large body of evidence has shown that these IDRs also play an important role in catalysing liquid–liquid phase separation of proteins, thereby organizing them into membrane-less biomolecular condensates [125]. By doing so, IDRs are fundamental to a wide range of cellular processes. In DNA repair, liquid–liquid phase separation is thought to enable the partitioning of relevant repair factors and simultaneously facilitate the required nucleic acid remodelling [126]. However, these same IDRs that are functionally so important also put proteins at the risk of aggregation. For liquid–liquid phase separation to occur, the local concentration of IDR proteins needs to be maintained at a very narrow bandwidth, just exceeding their solubility limit. As a result, biomolecular condensates are thought to be metastable, which is why they need to be regulated tightly to prevent aberrant phase transitions [127]. To this end, functional phase separation events are believed to rely heavily on the PQC network.

Situations of proteotoxic stress (i.e. where the regulatory capacity of the PQC network is insufficient) may lead to uncontrolled phase separation, causing condensates to irreversibly transition from a dense state to a solid aggregate. An example of this is TDP-43, which as described earlier is involved in RNA processing and DNA repair [128]. TDP-43 has a largely disordered C-terminal domain that drives liquid de-mixing under physiological conditions [129], a process thought to be regulated by molecular chaperones [130,131]. However, during stress, TDP-43 de-mixing can no longer be properly controlled, causing it to rapidly overshoot into an aggregated, proteotoxic state [129]. Similar molecular cascades may very well be responsible for the frequently observed sequestration of DNA repair factors discussed above into protein aggregates associated with neurodegeneration.

Additionally, there is evidence to suggest that amyloid precursor protein (APP), the precursor protein of amyloid-β aggregates, may also have a role in promoting DNA repair. In mammalian cell culture, APP interacts with the neuronal adaptor protein Fe65 to promote the chromatin remodelling required for the repair of DSBs (via histone acetyl transferase Tip60) [132] (figure 2). The C655F mutant of Fe65 (which is unable to bind to APP) cannot rescue the increased DNA damage observed in Fe65 deficient mouse embryonic fibroblasts [132]. This raises the possibility that the formation of cytoplasmic aggregates of amyloid-β might impair the physiological DDR repair the activity of APP.

4. DNA damage leading to loss of protein quality control

As discussed, protein aggregation-induced DNA damage is rapidly emerging as a contributing factor in the aetiology of many age-related neurodegenerative disorders. Importantly, the relationship between protein homeostasis and genome stability is a two-way street—aggregation of specific proteins like amyloid-β, Tau, mutant Htt and α-synuclein can impact genome stability, but conversely, genome instability can also dramatically affect the proteome [133]. This is clearly exemplified by known genetic alterations in more than 30 human genes that are strongly associated with protein aggregation and disease [134]. These alterations include (mostly missense substitution) mutations (e.g. in α-synuclein, Tau, transthyretin) and various nucleotide repeat expansions (ranging from CAG in HD and various SCAs, to C9ORF72 associated with ALS). In all these cases, protein homeostasis is threatened as a direct consequence of inherited or de novo genetic alterations in the germline, resulting in either the destabilization of native proteins, or in the formation of aberrant protein conformations that are prone to aggregate [134].

4.1. Gene copy number variation and protein stress

However, the connection between genome instability, loss of protein homeostasis and disease likely extends further. Larger chromosomal abnormalities can also result in potentially harmful transcript changes. For example, aneuploidy and gene copy number variations result in higher concentrations of protein that can drive proteotoxic stress [135–138]. This problem becomes especially pronounced when the genes involved encode components of stable multi-protein complexes relying on defined stoichiometries to fulfil their cellular function. Changes in the expression of any of these complex constituents can rapidly drive the excess of other components to aggregate, posing an added burden on the PQC network [139]. Although the proteome instability resulting from such dysregulated gene expression has been appreciated for years, it is gradually moving centre stage as a primary driver of dysfunction and disease [140].

4.2. DNA damage and protein stress

Recent single-cell sequencing studies have shown that a range of these ‘locked-in’ genetic alterations, including mutations and structural variants, can accumulate in somatic cells during ageing [141,142]. In addition, persistent global DNA damage can also challenge protein homeostasis by blocking transcription or, if bypassed, induce transcriptional mutagenesis, resulting in dysregulated gene expression or mutant protein production [143]. In line with a profound proteome destabilizing impact of genome instability, the impairment of certain genome maintenance components has also been
associated with proteome instability, although it is not always clear to what extent reduced DNA repair capacity is the causal factor. For example, the loss of the central DDR kinase ATM, involved in DSB repair, cell cycle regulation and cell death, leads to widespread protein aggregation, but this has been largely attributed to a signalling role in protein homeostasis, independent of genome maintenance itself [144]. More direct evidence supporting an impact of reduced genome maintenance comes from recent work showing that in mismatch repair-deficient tumours, the high mutation burden destabilizes the proteome, resulting in the accumulation of toxic protein aggregates that profoundly reduce cellular fitness [145]. How genome instability impacts global protein homeostasis over time, and to what extent this is relevant for disease and degeneration, is still poorly understood, but it is quickly surfacing as an extremely relevant field of research.

5. Future perspectives and conclusion

Ageing is characterized by both a loss of protein homeostasis and genome instability [146]. The brain is highly susceptible to both these events, as exemplified by the many neurodegenerative diseases hallmarked by the accumulation of protein aggregates, and by genetic DNA repair disorders characterized by pronounced neurodegeneration. Whether loss of protein homeostasis and genome instability are connected, and to what extent, remains unclear.

Recent evidence of a close relationship points towards increased DNA damage or reduced DNA repair capacity in the presence of neurodegeneration-associated proteins. However, there are still many key questions that remain unanswered. For example, it is not clear in which manner protein aggregates can directly cause DNA damage or indirectly impair the cellular DNA repair capacity. On the other hand, an increasing number of studies indicate that DNA damage might lead to a loss of protein homeostasis. It will therefore be important to determine if DNA damage has a causal role or is rather a collateral response of brain ageing; and/or, if a loss of protein homeostasis plays a role in the early stages of the disease or rather represents the end stage of a series of separate cellular responses, including DNA damage itself. To shed light on a possible causal relationship between the loss of protein homeostasis and DNA damage, a deeper understanding of the dynamic genome-proteome relationship is required. However, detailed proteogenomic characterization of somatic material is still in its infancy. The complexity of the brain and the low availability of patient post-mortem material in the early stages of pathology create an extra degree of difficulty. Nevertheless, promising recent advances in in vitro neuronal differentiation techniques and brain organoid cultures will aid in future progress. A combination of refined model systems and proteogenomic characterization will be needed to untangle the mechanisms that underlie the relationship between genotoxicity and proteotoxicity and how these responses contribute to neurodegeneration.

This review highlights that loss of protein homeostasis and genome instability contribute to neurodegeneration in a concerted manner. Understanding the underlying mechanisms connecting the PQC system and the DDR might lead to the identification of new therapeutic interventions that could benefit patients affected by neurodegenerative diseases and DNA repair disorders, as well as many cancer-surviving patients suffering from long-lasting adverse effects of DNA damage-inducing treatments.

Abbreviations

- 53BP1: Tumour suppressor p53-binding protein
- AAV: Adeno-associated virus
- AD: Alzheimer’s disease
- ALS: Amyotrophic lateral sclerosis
- APP: Amyloid precursor protein
- aMCI: Amnestic mild cognitive impairment
- AOA1: Ataxia-oculomotor apraxia type 1
- AT: Ataxia-telangiectasia
- ATM: Ataxia-telangiectasia mutated
- BARD1: BRCA1-associated RING domain protein 1
- BER: Base excision repair
- BRCA1: Breast cancer type 1 susceptibility protein
- ChiP: Chromatin immunoprecipitation
- CS: Cockayne syndrome
- DDR: DNA damage response
- DNA: Deoxyribonucleic acid
- DSB: Double-strand break
- EMSA: Electrophoretic mobility shift assay
- Fe65: Protein encoded by APBB1 (amyloid beta precursor protein binding family B member 1)
- FA: Fanconi anaemia
- FUS: Fused in Sarcoma
- HAP1: Human near haploid cells
- HD: Huntington’s disease
- HDAC1: Histone deacetylase 1
- HR: Homologous recombination
- Ht: Huntingtin
- IDR: Region of intrinsic disorder
- iPSC: Induced pluripotent stem cell
- KD: Knockdown
- KO: Knockout
- Ku70: Protein encoded by gene XRCC6 (X-ray repair cross complementing 6); Ku antigen, 70kDa
- LigIII: DNA ligase 3
- MMIR: DNA mismatch repair
- Mre11: Meiotic recombination 11
- MRN: Mre11/Rad50/Nbs
- mtDNA: Mitochondrial DNA
- NAC: N-acetylcysteine
- Nbs1: Nijmegen breakage syndrome 1
- NER: Nucleotide excision repair
- NES: Nuclear export signal
- NHEJ: Non-homologous end joining
- NIMA: Never in mitosis, gene A
- NLS: Nuclear localization signal
- NPC: Neuronal progenitor stem cell
- OE: Overexpression
- OGG1: 8-oxoguanine DNA glycosylase
- PBMC: Peripheral blood mononuclear cell
- PD: Parkinson’s disease
- PFF: Pre-formed fibrils
- PFF-syn: α-synuclein pre-formed fibrils
- PNKP: Polynucleotide kinase 3-phosphatase
- polyQ: Polyglutamine
References

1. United Nations, Department of Economic and Social Affairs, Population Division. 2019 World Population Prospects 2019, Online Edition. Rev. 1. (See https://population.un.org/wpp/Download/Standard/Population/)

2. Sanchez-Martín P, Komatsu M. 2018 p62/SQSTM1 - steering the cell through health and disease. J. Cell Sci. 131, jcs222836. (doi:10.1242/jcs. 222836)

3. Yang Y, Klionsky DJ. 2020 Autophagy and disease: unanswered questions. Cell Death Differ. 27, 858–871. (doi:10.1038/s41418-019-0490-9)

4. Kampina HH, Bergink S. 2016 Heat shock proteins and nuclear events as regulators of nonapoptotic forms of cell death. Oncogene 39, 1–16. (doi:10.1038/s41388-019-0980-6)

5. Hopp MS, Kasturi P, Hartl FL. 2019 The proteostasis network and its decline in ageing. Nat. Rev. Mol. Cell Biol. 20, 421–435. (doi:10.1038/s41580-019-0101-y)

6. Hartl FL, Bracher A, Hayer-Hartl M. 2011 Molecular chaperones in protein folding and proteostasis. Nature 475, 324–332. (doi:10.1038/nature10137)

7. Balch WE, Morimoto RI, Dillin A, Kelly JW. 2008 Adapting proteostasis for disease intervention. Science 319, 916–919. (doi:10.1126/science.1141448)

8. Ueda T, Retzlaff M, Roos T, Frydman J. 2011 Cellular ribosome-associated protein quality control. Cold Spring Harb. Perspect. Biol. 3, a004374. (doi:10.1101/ cshperspect.a004374)

9. Hanahan D, Weinberg RA. 2011 Hallmarks of cancer: the next generation. Cell 144, 646–674. (doi:10.1016/j.cell.2011.02.013)

10. Alexandrov LB et al. 2020 The repertoire of mutational signatures in human cancer. Nature 578, 94–101. (doi:10.1038/s41586-020-1943-3)

11. Gerstung M et al. 2020 The evolutionary history of 2,658 cancers. Nature 578, 122–128. (doi:10.1038/s41586-019-1907-7)

12. Jackson SP, Bartek J. 2009 The DNA-damage response in human biology and disease. Nature 461, 1071–1078. (doi:10.1038/nature08467)

13. Sirbu BM, Cortez D. 2013 DNA damage response: three levels of DNA repair regulation. Cold Spring Harb. Perspect. Biol. 5, a012724. (doi:10.1101/ cshperspect.a012724)

14. Prokhunova EA, Gorchowa RI, Zhivotovsky B, Kopeina GS. 2020 The DNA-damage response and nuclear events as regulators of nonapoptotic forms of cell death. Oncogene 39, 1–16. (doi:10.1038/s41388-019-0980-6)

15. Tubb A, Nussenweis E. 2017 Endogenous DNA damage as a source of genomic instability in cancer. Cell 168, 644–656. (doi:10.1016/j.cell.2017.01.002)

16. Chatterjee N, Walker GC. 2017 Mechanisms of DNA damage repair, and mutagenesis. Environ. Mol. Mutagen. 58, 255–323. (doi:10.1002/em.22087)

17. Petr MA, Tulika T, Carmona-Marin LM, Scheibye-Knudsen M. 2020 Protecting the aging genome. Trends Cell Biol. 30, 117–132. (doi:10.1016/j.tcb.2019.12.001)

18. McKinnon PJ. 2009 DNA repair deficiency and neurodegeneration. Nat. Rev. Neurosci. 10, 100–112. (doi:10.1038/nrn2559)

19. Riboldi GM, Samanta D, Frucht S. 2020 Ataxia Telangiectasia (Louis-Bar Syndrome). StatPearls. Treasure Island (FL). (Bookshelf ID: NBK519542)

20. Tada M, Yokoseki A, Sato T, Makishita T, Onodera O. 2010 Early-onset ataxia with oculomotor apraxia and hyponaebulminemia/ataxia with oculomotor apraxia 1. Adv. Exp. Med. Biol. 685, 21–33. (doi:10.1007/978-1-4419-6448-9_3)

21. Hafsi S, Badri T. 2020 Cockayne syndrome. StatPearls. Treasure Island (FL). (Bookshelf ID: NBK525948)

22. Adamek E, Vonsattel JP, Nixon RA. 1999 DNA strand breaks in Alzheimer's disease. Brain Res. 849, 67–77. (doi:10.1016/S0006-8993(99)02004-1)

23. Muller E, Boenigter ME, Ravid R, Swaab DF, Vija J. 1999 Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol. Aging 11, 169–173. (doi:10.1016/0197- 4538(90)90542-8)

24. Bender A et al. 2006 High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 38, 515–517. (doi:10.1038/ng1769)

25. Hegde ML, Gupta VB, Anitha M, Haniriksha T, Shankar SK, Muthane U, Subba Rao K, Jagannatha Rao KS. 2006 Studies on genomic DNA topology and stability in brain regions of Parkinson’s disease. Arch. Biochem. Biophys. 449, 143–156. (doi:10. 1016/j.abb.2006.02.018)

26. Polidori MC, Mecocci P, Browne SE, Senin U, Beal MF. 1999 Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neurosci. Lett. 272, 53–56. (doi:10.1016/S0304-3940(99)00578-9)

27. Browne SE, Bowling AC, MarGarvey U, Bajt MJ, Berger SC, Muqit MA, Bird ED, Beal MF. 1997 Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41, 646–653. (doi:10.1002/ana.410104154)

28. Jacobsen E, Beach T, Shen Y, Li R, Chang Y. 2004 Deficiency of the Mre11 DNA repair complex in Alzheimer's disease brains. Brain Res. Mol. Brain Res. 128, 1–7. (doi:10.1016/j.molbrainres.2004.05.023)

29. Shackelford DA. 2006 DNA end joining activity is reduced in Alzheimer's disease. Neurobiol. Aging 27, 596–605. (doi:10.1016/j.neurobiolaging.2005. 03.009)

30. Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL, Lee MK. 2006 Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26, 41–50. (doi:10.1523/ JNEUROSCI.4388-05.2006)

31. Suberbielle E, Sanchez PE, Kravitz AV, Wang X, Ho K, Eiertoren K, Devidze N, Kreiter AC, Macke L. 2013 Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by...
amyloid-β. Nat. Neurosci. 16, 613–621. (doi:10.1038/nn.3356)

32. Jang JH. 2002 Suth YJ. β-amyloid induces oxidative DNA damage and cell death through activation of c-Jun N terminal kinase. Ann. N Y Acad. Sci. 973, 228–236. (doi:10.1111/j.1749-6632.2002.tb04639.x)

33. Suram A, Hegele ML, Rao KS. 2007 A new evidence for DNA nicking property of amyloid β-peptide (1-42): relevance to Alzheimer’s disease. Arch. Biochem. Biophys. 463, 245–252. (doi:10.1016/j.abb.2007.03.015)

34. Violet M et al. 2014 A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hypothermic conditions. Front. Cell. Neurosci. 8, 84. (doi:10.3389/fncel.2014.00084)

35. Hua Q, He RO. 2002 Effect of phosphorylation and aggregation on Tau binding to DNA. Protein Pept. Lett. 9, 349–357. (doi:10.1215/20996623200865)

36. Bukar Maina M, Al-Hilaly YK, Serpell LC. 2016 Nuclear Tau and its potential role in Alzheimer’s disease. Biomolecules 6, 9. (doi:10.3390/biom6010009)

37. Shanbhag NM, Evans MD, Mao W, Nana AL, Seeley WW, Adame A, Rissman RA, Masliah E, Mucke L. 2010 Oxidative damage in nucleic acids and neuronal DNA and RNA protection induced by disease. Neuropathol. Commun. 7, 9. (doi:10.3368/jn.9.08111-6)

38. Wang FY, Pan L, Su SC, Quinn EJ, Sasaki M, Jimenez JC, Mackenzie IRA, Huang EJ, Tsai L-H. 2013 Interaction of FUS and HDAC5 regulates DNA damage response and repair in neurons. Nat. Neurosci. 16, 1383–1391. (doi:10.1038/nn.3514)

39. Qiu H et al. 2014 ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J. Clin. Invest. 124, 981–999. (doi:10.1172/JCI72723)

40. Enokido Y et al. 2010 Mutant huntingtin impairs Ku70-mediated DNA repair. J. Cell Biol. 189, 425–443. (doi:10.1083/jcb.200905138)

41. Van Drie JH. 2011 Protein folding, protein homeostasis, and cancer. Chin. J. Cancer 30, 124–137. (doi:10.5322/jc.010162)

42. Whitesell L, Lindquist S. 2009 Inhibiting the transcription factor HSFl as an anticancer strategy, Expert Opin. Ther. Targets 13, 469–478. (doi:10.1517/147282200900283697)

43. Dai C, Whitesell L, Rogers AB, Lindquist S. 2007 Heat shock factor 1 is a powerful multifaceted modulator of carcinogenesis. Cell 130, 1005–1018. (doi:10.1016/j.cell.2007.07.020)

44. Sannino S, Brodsky JL. 2017 Targeting protein quality control pathways in breast cancer. BMC Biol. 15, 109. (doi:10.1186/s12955-017-0449-0)

45. Coppe F, Migliore L. 2015 DNA damage in neurodegenerative diseases. Mutat. Res. 776, 84–97. (doi:10.1016/j.mfrmm.2014.11.010)

46. Collins AR, Oscoal AA, Brungob G, Galvoa I, Giovannelli L, Krusevzki M, Smith CC, Stetina R. 2008 The comet assay: topical issues. Mutagenesis 23, 143–151. (doi:10.1039/mutation2007).

47. Lima MM, Miranda A, Nascimento AC, Silva AD, de Abreu GS, de Souza Filho SP, dos Santos LR. 2016 A major role for Tau in Alzheimer’s disease. Acta Neuropathol. Dis. 19, 311–323. (doi:10.2323/jaad-2010-1221)

48. Kim GH, Kim JE, Rhie SJ, Yoon S. 2015 The role of oxidative stress in neurodegenerative diseases. Exp. Neurol. 24, 325–340. (doi:10.1016/j.expneurol.2014.24.432)

49. Lu B, Guo S. 2020 Mechanisms linking mitochondrial dysfunction and protein aggregation. Trends Cell Biol. 30, 317–328. (doi:10.1016/j.tcb.2020.01.008)

50. Johri A, Beal MF. 2012 Mitochondrial dysfunction in neurodegenerative diseases. J. Pharmacol. Exp. Ther. 342, 619–630. (doi:10.1124/jpet.112.192138)

51. Guo C, Sun L, Chen X, Zhang D. 2013 Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neuro Rep. 8, 2003–2014. (doi:10.1396/jissn.1673-5374.2013.21.009)

52. Haas RH. 2019 Mitochondrial dysfunction in aging and diseases of aging. Biology 8, 48. (doi:10.3390/biology80200048)

53. Wu Y, Chen M, Jiang J. 2019 Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling. Mitochondrion 49, 35–45. (doi:10.1016/j.mito.2019.07.003)

54. Fishel ML, Vasko MR, Kelley MR. 2007 DNA repair in neurons: so if they don’t divide what’s to repair? Mutat. Res. Fundam. Mol. Med. Mutagen. 614, 24–36. (doi:10.1016/j.mrfmm.2006.06.007)

55. Pollf AR, Godoin G, Bart G, Kostina H, Gniatultin R. 2014 The role of oxidative stress in degeneration of the neurovascular junction in amyotrophic lateral sclerosis. Front. Cell. Neurosci. 8, 131. (doi:10.3389/fncel.2014.00131)

56. Rakhit R, Chakrabarty A. 2006 Structure, folding, and misfolding of Cu,Zn superoxide dismutase.
Defective DNA base excision repair in brain from mice lacking the DNA repair enzyme XPG induces DNA damage accumulation in ALS patient-derived motorneurons. Stem Cell Res. 30, 150–162. (doi:10.1016/j.scr.2018.06.005)

Renard L, Picher-Martel V, Codron P, Julien JP. 2019 Key role of UBQLN2 in pathogenesis of amyotrophic lateral sclerosis and frontotemporal dementia. Acta Neuropathol. Commun. 7, 103. (doi:10.1186/s41478-019-01758-7)

Subudhi L, Shorter J. 2018 Ubiquitin 2: shuttling clients out of phase? Mol. Cell. 69, 919–921. (doi:10.1016/j.molcel.2018.02.030)

Yang H, Yue HW, He WT, Hong JY, Jiang LL, Hu HY. 2018 PolyQ-expanded huntingtin and ataxin-3 sequester ubiquitin adaptors HHR23B and UBQLN2 into aggregates via conjugated ubiquitin. FASEB J. 32, 2923–2933. (doi:10.1096/fj.201700889R)

Meerang M et al. 2011 The ubiquitin-selective segrege VCP/p97 orchestrates the response to DNA double-strand breaks. Nat. Cell Biol. 13, 1376–1382. (doi:10.1038/nclb2367)

Bergink S, Ammon T, Kern M, Schermelleh L, Leonhardt H, Jentsch S. 2013 Role of Cde48/p97 as a SUMO-targeted segrege curbing Rad51–Rad52 interaction. Nat. Cell Biol. 15, 526–532. (doi:10.1038/nclb2729)

Stach L, Freemont PS. 2017 The AAA + ATPase p97, a cellular multitool. Biochem. J. 474, 2953–2976. (doi:10.1042/BCJ20160783)

Ferlazzo ML, Sonzogni L, Granzotto A, Bodgi L, Lartin O, Devic C, Vogin G, Pereira S, Foray N. 2014 Mutations of the Huntington’s disease protein impact on the AT-dependent signaling and repair pathways of the radiation-induced DNA double-strand breaks: corrective effect of statins and bisphosphonates. Mol. Neurobiol. 49, 1200–1211. (doi:10.1007/s12035-013-5691-7)

Maiuri T, Moce AJ, Hung CL, Xia J, van Roon-Mom W, Tranutt R. 2017 Huntington’s is a scaffolding protein in the ATM oxidative DNA damage response complex. Hum. Mol. Genet. 26, 395–406. (doi:10.1093/hmg/ddw395)

Ashkelon G et al. 2018 Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington’s disease patients. Sci. Rep. 8, 9817. (doi:10.1038/s41598-018-27985-y)

Gao R et al. 2019 Mutant huntingtin impairs PKNP and ATXN3, disrupting DNA repair and transcription. ELife 8, e42988. (doi:10.7554/eLife.42988)

Zoghbi HY, Orr HT. 2000 Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217–247. (doi:10.1146/annurev.neuro.23.1.217)

Costa Mdo C, Paulson HL. 2012 Toward understanding Machado-Joseph disease. Prog. Neurobiol. 97, 239–257. (doi:10.1016/j.pneurobiol.2011.11.006)

Rodríguez-Lebrón E, Costa Mdo C, Luna-Cancalon K, Peron TM, Fischer S, Boudreau RL, Davidson BL, Paulson HL. 2013 Silencing mutant ATXN3...
expression resolves molecular phenotypes in SCA3 transgenic mice. *Mut. Ther.* **21**, 1909–1918. (doi:10.1038/mt.2013.152)

118. Gao R et al. 2015 Inactivation of PNKP by mutant ATM triggers apoptosis by activating the DNA damage-response pathway in SCA3. *PLoS Genet.* **11**, e1004834. (doi:10.1371/journal.pgen.1004834)

119. Ackermann L, Schell M, Pokrzywa W, Kevei E, Gartner A, Schumacher B, Hoppe T. 2016 E4 ligase-specific ubiquitination hubs coordinate DNA double-strand-break repair and apoptosis. *Nat. Struct. Mol. Biol.* **23**, 995–1002. (doi:10.1038/nsmb.3296)

120. Pfeiffer A et al. 2017 A taxin-3 stabilizes the MDC1-dependent DNA double-strand break response by countering the SUMO-targeted ubiquitin ligase RNF4. *EMBO J.* **36**, 1066–1083. (doi:10.15252/embj.201695151)

121. Yang H, Hu HY. 2016 Sequestration of cellular components by TDP-43 and FUS interactomes induced by DNA damage. *Nat. Chem.* **7**, 7128. (doi:10.1038/ncchem.1466)

122. He B, Wang K, Liu Y, Xue B, Uversky VN, Dunker AK. 2009 Predicting intrinsic disorder in proteins: an overview. *Cell Res.* **19**, 929–949. (doi:10.1038/cr.2009.87)

123. Wallam A, Kesten C. 2020 Common functions of disordered proteins in aneuploidy. *Int. J. Mol. Sci.* **21**, 2105. (doi:10.3390/ijms21062105)

124. Zhou HX, Pang X, Lu C. 2012 Rate constants and mechanisms of intrinsically disordered proteins binding to structured targets. *Phys. Chem. Chem. Phys.* **14**, 10 466–10 476. (doi:10.1039/c2cp41196b)

125. Franzmann TM, Alberti S. 2019 Prion-like low-complexity protein sequences: key regulators of protein solubility and phase behavior. *J. Biol. Chem.* **294**, 7128–7136. (doi:10.1074/jbc.M118.001190)

126. Shorter J. 2016 Membraneless organelles: phasing in and out. *Nat. Chem.* **8**, 528–530. (doi:10.1038/nchem.2534)

127. Alberti S, Hyman AA. 2016 Are aberrant phase transitions a driver of cellular aging? *Bioessays* **38**, 959–968. (doi:10.1002/bies.201600042)

128. Kawaguchi T, Rollins MG, Moinpour M, Morera AA, Ebmeier CC, Old WM, Schwartz JC. 2020 Changes to the TDP-43 and FUS interactomes induced by DNA damage. *J. Proteome Res.* **19**, 360–370. (doi:10.1021/acs.jproteome.9b00575)

129. Gaoet-Rosa F, Lu S, Yu H, Chen C, Melamed Z, Guo L, Shorter J, Da Cruz S, Cleveland DW. 2019 Cytoplasmic TDP-43 de-mixing independent of stress granule drives inhibition of nuclear import, loss of neuronal TDP-43, and cell death. *Neuron* **102**, 339–357.e7. (doi:10.1016/j.neuron.2019.02.038)

130. Udan-Johns M, Bengoechea R, Bell S, Shao J, Diamond MI, True HL, Weihl CC, Baloh RH. 2014 Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones. *Hum. Mol. Genet.* **23**, 157–170. (doi:10.1093/hmg/ddt408)

131. Choi KJ, Tsoi PS, Moosa MM, Paullucci-Holthauzen A, Liao SJ, Ferreon JC, Ferreon ACM. 2018 A chemical chaperone decouples TDP-43 disordered protein domain phase separation from fibrillation. *Biochemistry* **57**, 6822–6826. (doi:10.1021/acs.biochem.8b01051)

132. Sturte M, Minopoli G, Passaro F, Raia M, Vecchio LD, Russo T. 2009 Fe65 is required for Tip60-directed histone H4 acetylation at DNA strand breaks. *Proc. Natl Acad. Sci. USA* **106**, 5093–5098. (doi:10.1073/pnas.0810869106)

133. Hulting W, Bergink S. 2020 Locked in a vicious cycle: the connection between genomic instability and a loss of protein homeostasis. *Genome Instability Dis.** 2**, 1–23. (doi:10.1007/s12374-020-00027-6)

134. Chiti F, Dobson CM. 2017 Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. *Annu. Rev. Biochem.* **86**, 27–68. (doi:10.1146/annurev-biochem-061516-045115)

135. Stingele S, Steehr G, Peplovska K, Cox J, Mann M, Storchova Z. 2012 Global analysis of genome, transcriptome and proteome reveals the response to aneuploidy in human cells. *Mol. Syst. Biol.* **8**, 608. (doi:10.1038/msb.2012.40)

136. Oromedia AB, Amon A. 2014 Aneuploidy: implications for protein homeostasis and disease. *Dis. Model Mech.* **7**, 15–20. (doi:10.1242/dmm.013391)

137. Perez-Rodriguez D et al. 2019 Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNP analysis and single cell sequencing. *Acta Neuropathol. Commun.* **7**, 219. (doi:10.1186/s40478-019-0873-5)

138. Rovelet-Lecrux A et al. 2006 APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. *Nat. Genet.* **38**, 24–26. (doi:10.1038/ng1718)

139. Brennan CM, Vailes LP, Wells JN, Santaguida S, Paulo JA, Storchova Z, Harper JVH, Marsh JA, Amon A. 2019 Protein aggregation mediates stoichiometry of protein complexes in aneuploid cells. *Genes Dev.* **33**, 1031–1047. (doi:10.1101/gad.327494.119)

140. Zhu PJ, Khatiwada S, Cai Y, Reineke LC, Douling SW, Kim JJ, Li W, Walter P, Costa-Mattioli M. 2019 Activation of the IRS mediates the behavioral and neurophysiological abnormalities in Down syndrome. *Science* **366**, 843–849. (doi:10.1126/science.aaw5185)

141. Niedernhofer LJ, Gurkar AU, Wang Y, Vijg J, Hoeijmakers JHH, Robbins PD. 2018 Nuclear genomic instability and aging. *Annu. Rev. Biochem.* **87**, 295–322. (doi:10.1146/annurev-biochem-062917-045108)

142. Forsberg LA et al. 2012 Age-related somatic structural changes in the nuclear genome of human blood cells. *Am. J. Hum. Genet.* **90**, 217–228. (doi:10.1016/j.ajhg.2011.12.009)

143. Lans H, Hoeijmakers JHH, Vermeulen W, Marteijn JA. 2019 The DNA damage response to transcription stress. *Nat. Rev. Mol. Cell Biol.* **20**, 766–784. (doi:10.1038/s41580-019-0169-4)

144. Lee JH, Mand MR, Kao CH, Zhou Y, Ryu SW, Richards AL, Coon JJ, Pauli TT. 2018 ATM directs DNA damage responses and proteostasis via genetically separable pathways. *Sci. Signal.* **11**, eaan5598. (doi:10.1126/scisignal.aan5598)

145. McGraith DJ et al. 2020 Proteome instability is a therapeutic vulnerability in mismatch repair-deficient cancer. *Cancer Cell.* **37**, 371–386.e12. (doi:10.1016/j.ccell.2020.01.011)

146. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. 2013 The hallmarks of aging. *Cell* **153**, 1194–1217. (doi:10.1016/j.cell.2013.05.039)